Kenvue’s TYLENOL With Naproxen Shows Lasting Pain Relief
Fort Washington, Pennsylvania, U.S., September 8, 2026 New clinical evidence presented at PAINWeek 2026 highlights the potential of a...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Fort Washington, Pennsylvania, U.S., September 8, 2026 New clinical evidence presented at PAINWeek 2026 highlights the potential of a...
Oxford, United Kingdom, September 8, 2026 Brainomix and Endeavor BioMedicines have presented positive results from a quantitative image analysis...
San Diego, California, U.S., September 8, 2026 Inhibrx Biosciences, Inc. has reported positive primary endpoint results from the randomized...
